abstract |
The invention discloses an IL-2 derivative. By introducing at least one cysteine residue on the basis of IL-2, the binding plane of the IL-2 derivative and the alpha receptor subunit is partially or completely blocked, While substantially retaining the affinity for the β and γ receptor subunit complexes. |